Journal article
Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design
Abstract
BACKGROUND: The differential impact of the number of prior lines of therapy and the setting of prior therapy (perioperative or metastatic) is unclear in advanced urothelial carcinoma.
PATIENTS AND METHODS: Ten phase II trials of salvage chemotherapy, biologic agent therapy, or both, enrolling 731 patients, were available. Data on the number of prior lines of therapy and the setting of prior therapy were required in addition to known previously …
Authors
Pond GR; Bellmunt J; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A
Journal
Clinical Genitourinary Cancer, Vol. 13, No. 1, pp. 71–79
Publisher
Elsevier
Publication Date
February 2015
DOI
10.1016/j.clgc.2014.06.004
ISSN
1558-7673